What is Kanabo Group PLC?
Kanabo Group Plc, a digital health company, engages in the research, development and commercialization of cannabis-derived formulations and therapeutic inhalation devices.
KNB · Verdict
Moderate reward · elevated risk
KNB stands out on balance sheet and growth, but watch the volatility signal.
Based on 88% data coverage
KNB · Verdict
Current ratio 5.04
Rev +146.2% CAGR · earnings +322.4%
Above average
Weak vs peers
-892% net margin · -83% ROE
-341% free-cash-flow margin
Model-based scoring. For information only — not financial advice.
Kanabo Group Plc, a digital health company, engages in the research, development and commercialization of cannabis-derived formulations and therapeutic inhalation devices. It operates through Primary Care and Secondary Care segments. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 1.42M.
The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.